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Background: Respiratory epithelium integrity impairment caused by intensive exercise may lead to exercise-induced
bronchoconstriction. Clara cell protein (CC16) has anti-inflammatory properties and its serum level reflects changes in
epithelium integrity and airway inflammation. This study aimed to investigate serum CC16 in elite athletes and to seek
associations of CC16 with asthma or allergy, respiratory tract infections (RTIs) and immune response to respiratory
pathogens.
Methods: The study was performed in 203 Olympic athletes. Control groups comprised 53 healthy subjects and
49 mild allergic asthmatics. Serum levels of CC16 and IgG against respiratory viruses and Mycoplasma pneumoniae
were assessed. Allergy questionnaire for athletes was used to determine symptoms and exercise pattern. Current
versions of ARIA and GINA guidelines were used when diagnosing allergic rhinitis and asthma, respectively.
Results: Asthma was diagnosed in 13.3% athletes, of whom 55.6% had concomitant allergic rhinitis. Allergic rhinitis
without asthma was diagnosed in 14.8% of athletes. Mean CC16 concentration was significantly lower in athletes
versus healthy controls and mild asthmatics. Athletes reporting frequent RTIs had significantly lower serum CC16 and
the risk of frequent RTIs was more than 2-fold higher in athletes with low serum CC16 (defined as equal to or less than
4.99 ng/ml). Athletes had significantly higher anti-adenovirus IgG than healthy controls while only non-atopic athletes
had anti-parainfluenza virus IgG significantly lower than controls. In all athletes weak correlation of serum CC16 and
anti-parainfluenza virus IgG was present (R = 0.20, p < 0.01). In atopic athletes a weak positive correlations of CC16 with
IgG specific for respiratory syncytial virus (R = 0.29, p = 0.009), parainfluenza virus (R = 0.31, p = 0.01) and adenovirus
(R = 0.27, p = 0.02) were seen as well.
Conclusions: Regular high-load exercise is associated with decrease in serum CC16 levels. Athletes with decreased
CC16 are more susceptible to respiratory infections. Atopy may be an additional factor modifying susceptibility to
infections in subjects performing regular high-load exercise.
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Strenuous exercise characteristic of endurance sports is
believed to have a detrimental effect on the integrity of
the structure of the respiratory epithelium. Such damage
may lead to increased bronchial hyperresponsiveness
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reproduction in any medium, provided the orprevalence of exercise-induced bronchoconsriction ob-
served in elite endurance athletes [1-4]. Endurance sports
may be also associated with increased susceptibility to
respiratory infections [5], which in turn, may exert a de-
structive effect on the airway epithelium.
Various proteins have been assessed as potentially use-
ful tools in monitoring airway inflammation and epithe-
lial damage [6-9]. Clara cell secretory protein (CC16), a
protein secreted by non-ciliated cells of the bronchioles,
has also been studied as an indicator of epithelial barrieral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Table 1 Division of athletes into endurance and
non-endurance group based on sport and discipline
Sport Number of
athletes
Endurance sports (n = 80)
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been undertaken to explain its role in airway inflamma-
tion and, although its function has not been fully eluci-
dated, CC16 is known to have anti-inflammatory and
anti-oxidative properties [10]. However, CC16 levels in
serum depend not only on its production by Clara cells
and possible leakage through the disrupted epithelial
barrier, but also on renal clearance. Moreover, multiple
factors may influence final CC16 serum concentration
(e.g., diurnal variation, age, ethnicity, atmospheric condi-
tions, allergen exposure, exercise). As a result of these
concerns the utility of serum CC16 level measurements
in monitoring of the activity of pulmonary disease, air-
way inflammation and chronic or acute epithelial dam-
age is disputed (reviewed by LaKind et al. [11]).
Changes in serum CC16 levels were observed after
acute, short-lasting exposure to exercise or provocative
or irritating stimuli. Non-specific challenges with exer-
cise and eucapnic voluntary hyperpnea (EVH) resulted
in increased urinary CC16 levels [12,13]. In adult swim-
mers, exposure to trichloramine, a by-product of swim-
ming pool disinfection, caused transient increase in serum
CC16 levels while no such changes were observed in
children [14].
Chronic airway inflammation may also be associated
with shifts in local and systemic presence of CC16. Dur-
ing pollen season, CC16 in nasal lavage fluid is de-
creased in subjects with birch pollen-induced allergic
rhinitis [15]. Decreases in serum CC16 levels in asth-
matics are independent of their atopic status and correl-
ate positively with duration of disease [16]. CC16 is
believed to have not only immunomodulatory and anti-
inflammatory properties but also to possibly influence
the anti-infectious response: an increased persistence
of viruses and prolonged viral-specific gene expression
were observed in CC16-deficient mice in response to
RSV infection [17].
The aim of this study was to investigate the airway epi-
thelium inflammation and potential damage in competi-
tive athletes, as reflected by changes in serum CC16
levels. Secondly, we sought to identify possible associa-
tions of serum CC16 level with pattern of exercise, asthma
or allergy, frequent respiratory infections and the immune
response to respiratory pathogens reflected by pathogen-
specific IgG levels in the serum.
Materials and methods
Subjects
The study group consisted of 203 athletes (142 males
and 61 females) preparing for the Olympic Games in
Beijing in 2008 who were included into Allergy and
Asthma in Polish Olympic Athletes study (A2POLO)
which was a part of the multicentre Olympic Study per-
formed within the framework of GA2LEN (Global Allergyand Asthma European Network of Excellence project).
One hundred and forty-six (71.9%) of the recruited athletes
were eventually included into the Polish Olympic Team for
the Beijing games. The athletes represented 21 sport disci-
plines which, according to the predominant pattern of
exercise, were divided into endurance (80 athletes) and
non-endurance (123 athletes) (Table 1).
The protocol of the study was approved by the Bioethics
Commission of the Medical University of Lodz. All sub-
jects gave written informed consent for participation.
Bronchial asthma and allergic rhinitis were diagnosed
based on criteria published in their respective Global
Initative for Asthma (GINA) and Allergic Rhinitis and
its Impact on Asthma (ARIA) guidelines [18,19].
Two control groups of subjects who had never per-
formed sport at a competitive level were recruited as a
reference for serum concentrations of lung specific pro-
tein. The first group consisted of 53 healthy subjects
without history of allergy or any pulmonary condition
whereas the second control group comprised 49 allergic
non-smoking mild asthmatics with well controlled symp-
toms, diagnosed according to GINA [18] and receiving
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detailed characteristics of the study and control groups are
shown in Tables 2 and 3.
The following subgroups of athletes were distinguished
for the purpose of further analysis: athletes diagnosed
with allergic rhinitis (n = 30); athletes diagnosed with aller-
gic asthma with or without concomitant rhinitis (n = 27);
and athletes without asthma or allergy (n = 146), basing on
the diagnosis established during clinical evaluation of ath-
letes. The data from an Allergy Questionnaire for Athletes
(AQUA) were analysed separately.
AQUA questionnaire
Data regarding type of sport, allergy symptoms and
history of respiratory infections, as well as demo-
graphical data, were acquired from the Allergy Ques-
tionnaire in Athletes (AQUA©) which was filled by
each athlete entering the study. The AQUA question-
naire, developed and validated by Bonini et al [20] in
Italian soccer players, is intended as an allergy screen-
ing tool in competitive athletes, with AQUA© score
values ≥5 described as having the best positive predict-
ive value for allergy. The questionnaire is protected by
copyright and its use in this study was kindly permitted
by the authors.
Lung function tests
Spirometry was performed according to criteria defined
by a joint ERS/ATS task force [21] using a Lungtest
1000 spirometer (MES, Kraków, Poland). Subjects re-
ceiving antiasthmatic treatment were asked to suspend
taking long-acting beta2-agonists for 24 hours, short-
acting beta2-agonists for 12 hours, inhaled steroids for
7 days and leukotriene modifiers for 5 days before lung
function testing. At least three measurements in the up-
right position were performed and the best result was
recorded. Reversibility test with bronchodilator was per-
formed only in athletes. For this purpose, 400 μg of
salbutamol was administered by metered dose inhaler,
followed by spirometry measurement 15 minutes later.Table 2 Demographics and lung function parameters in healt
Healthy controls Asthma controls
No. of subjects 53 49
Males/Females 23/30 15/34
Age[years] (median; range) 28 (20-45) 29 (18-45)
Baseline FEV1 [% predicted]
(median;range)




MEF 25-75 [% predicted]
(median; range)
104 80*
*p < 0.05 vs. HC, all athletes, endurance athletes and non-endurance athletes;; ND, nChanges in forced expiratory volume in 1 s (ΔFEV1)
from before to after drug inhalation were calculated
according to the formula: 100 × (postsalbutamol FEV1 -
initial FEV1)/initial FEV1.
Laboratory measurements
Serum samples were obtained from 86% (n = 119) non-
endurance and 94% (n = 75) endurance athletes. The
remaining athletes were not available for blood sam-
pling due to training schedules. Blood was drawn into
Monovette tubes for serum (Sarstedt, Landskrona, Sweden).
Each sample was left to clot at room temperature for ca.
30 minutes. Subsequently, samples were centrifuged at
700 g for 10 minutes and serum was transferred to cryo-
tubes and frozen at –80°C for further analyses.
CC16 concentration was determined using Human
Clara Cell Protein ELISA kits (BioVendor Laboratory
Medicine, Inc., Modrice, Czech Republic) in accordance
with instructions provided by the manufacturer. Samples
were run in duplicate at a 25-fold dilution, following the
manufacturer’s recommendations. The lower CC16 de-
tection limit is 20 pg/ml.
The serum concentration of IgG antibodies against
parainfluenza virus 1,2 and 3 (PIV) was determined by
commercially available ELISA kit (DRG International,
Inc., Mountainside, NJ, USA). The threshold value for
positive anti-PIV IgG testing was 10 U/ml.
The serum concentrations of IgG against respiratory
syncytial virus (RSV), adenovirus and Mycoplasma pneu-
moniae were determined by commercially available semi-
quantitative ELISA kits (Orgenium Laboratories, Vantaa,
Finland) The threshold value for positive testing was 25
Enzyme Immunoassay Units (EIU).
Concentrations of serum IgG’s against repiratory path-
ogens were determined in athletes and healthy control
groups only.
Statistics
Statistical analyses were performed using Statistica (Statsoft
Polska, Krakow, Poland) and GraphPad Prism (Graphpadhy and asthmatic control subjects and in athletes
All athletes Endurance athletes Non-endurance athletes
203 80 123
142/61 60/20 82/41
26 (18-41) 25 26
103 (66-129) 106 (82-126) 100 (66-129)
4 (0-26) 4 (0-20) 4 (0-26)
97 (38-170) 96 (42-170) 98 (38-163)
ot done; HC, healthy controls
Table 3 Demographics and lung function parameters in healthy and allergic athletes
Athletes with rhinitis Athletes with asthma Athletes without asthma or allergy
No. of subjects 30 27 146
Males/Females 19/11 17/10 97/41
Age[years] (median; range) 26 25 26
Baseline FEV1 [% predicted] (median;range) 105 (80 – 129) 99 (66 – 117) 103 (81 – 125)
ΔFEV1post-salbutamol [%] (median; range) 4 (0 – 10) 10.5 (2 – 26)a 4 (0 – 20)
FVC [% predicted] (median; range) 101 (92 – 120) 108 (77 – 125) 106.5 (85 – 134)
FEV1/FVC (median; range) 0.81 (0.72 – 0.92) 0.77 (0.63 – 0.86) 0.81 (0.61 – 0.97)
MEF 25-75 [% predicted] (median; range) 98 (54 – 156) 82 (38 – 122)b 99 (42 – 170)
ap < 0.001 vs. athletes with rhinitis and athletes without asthma or allergy;
bp < 0.05 vs. athletes with rhinitis and athletes without asthma or allergy.
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Kolmogorov-Smirnov test with Lilliefors correction was
used to check for normality of values’ distribution. To
identify differences between groups, the Mann-Whitney
U test or Kruskal-Wallis test with Dunn’s post hoc test
were used where applicable. Correlations of age, total
IgE, lung function parameters, reversibility challenge re-
sults and levels of IgG against respiratory pathogens with
serum CC16 level were assessed with Spearman’s rank
correlation test.
The chi-square test with Yates’ correction was used for
between-the-group comparisons of percentage of posi-
tive tests for IgG against the presence of PIV, RSV,
adenovirus or M. pneumoniae.
Relationships between serum CC16 level and AQUA
score value with the presence of asthma/allergy symp-
toms and frequent respiratory infections were analysed
using logistic regression.
A P value less than 0.05 was considered statistically
significant in all analyses.
Results
Clinical features
Upon clinical evaluation, asthma was diagnosed in 27
athletes (13.3%) of whom 15 (55.6%) had concomitant
allergic rhinitis, whereas allergic rhinitis (without con-
comitant asthma) - in 30 subjects (14.8%).
An affirmative answer to the question “Do you fre-
quently suffer from upper respiratory infections (pha-
ryngitis, bronchitis, colds) or fever?” was given by 39
athletes (19.2%). No differences in the prevalence of self-
reported frequent infections were seen between atopic and
non atopic athletes (20.1% vs. 18.4%; p > 0.05, χ 2 test).
Lung function parameters did not differ significantly
between endurance and non-endurance athletes. No dif-
ferences were observed between athletes (endurance and
non-endurance) and any of the control groups – Table 2.
The median FEV1, FVC and FEV1/FVC values in asth-
matic athletes were not significantly different from thoseobserved in athletes with rhinitis and in non-asthmatic
non-allergic athletes. Median MEF25-75 values were sig-
nificantly lower in athletes with asthma as compared to
other athletes. Also, MEF25-75 values were significantly
reduced in asthmatic controls compared to the healthy
controls and the athletes – Table 2. The percentage in-
crease in FEV1 after salbutamol was significantly higher
in athletes with asthma than in non-asthmatics (10.5%
vs 4%; p < 0.001) – Table 3.
Serum CC16 and exercise pattern
Serum CC16 concentration was measured in 75 endur-
ance and 123 non-endurance athletes and in two control
groups of non-athletes. The mean serum CC16 con-
centration was significantly lower in the “all-athletes”
group than in healthy controls and asthmatic controls –
Figure 1. No differences in the serum CC16 concentrations
were observed between endurance and non-endurance
athletes (7.13 [5.09-9.43] vs. 6.67 [5.20-9.14] ng/ml;
medians with interquartile ranges, p > 0.05]). Consider-
ing possible noxious effect of trichloramines on airway
epithelium and Clara cell function, additional analysis
was performed to assess possible influence of competitive
swimming on serum CC16 levels. Exclusion of swim-
mers and triathletes (n = 8) did not significantly influ-
ence the serum CC16 level (6.79 [5.17-9.18] ng/ml without
swimmers and triathletes vs. 6.82 [5.14-9.17] ng/ml in
all athletes; medians with interquartile ranges, p > 0.05,
Mann-Whitney U test).
Serum CC16, allergic disease and respiratory infections
Levels of serum CC16 did not differ significantly between
atopic and non-atopic athletes (6.88 [5.37-9.15] vs. 6.68
[5.03-9.06] ng/ml; medians with interquartile ranges,
p > 0.05]). No association was found between CC16 levels
and self-reported asthma symptoms or between serum
CC16 and physician-diagnosed asthma or allergic rhin-
itis. However, in athletes reporting frequent upper re-
spiratory infections, the median serum CC16 levels were
Figure 1 Serum Clara cell protein (CC16) concentration in healthy controls (HC), mild asthmatic controls and in athletes. One dot
represents one subject. Medians with interquartile ranges are marked with horizontal lines.
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values 5.57 vs 7.03 ng/ml; respectively, p = 0.01, Mann-
Whitney U test) – Figure 2.
No significant correlation of serum CC16 with asthma,
baseline FEV1 or percentage of airway reversibility after
beta-agonist treatment was found in the all-athletes
group or in any of the athlete subgroups: ie, endurance,
non-endurance, allergic/asthmatic or healthy athletes.
Similarly, no correlations of serum CC16 with age or
lung function parameters were found in the control
groups.Figure 2 Serum CC16 levels in athletes reporting and not reporting f
questionnaire. Medians with interquartile ranges are marked with horizontalLogistic regression analysis using ‘serum CC16 ≤
4.99 ng/ml’ (considered as the low value) as an inde-
pendent variable showed that the risk of frequent URTIs,
as reported in the AQUA questionnaire, was significantly
higher in athletes with low serum CC16 (OR = 2.56; 95%
CI:1.19-5.50; p < 0.02). Also, the risk of declared nasal
symptoms, not identical with physician-diagnosed rhinitis,
was higher in athletes with serum CC16 ≤ 4.99 ng/ml
(OR = 2.21; 95% CI:1.10-4.47; p < 0.03).
No association was found between a serum CC16 level
lower than 4.99 ng/ml and diagnosis of allergic rhinitis,requent respiratory infections when completing the AQUA©
lines. One dot represents one subject. * p = 0.01, Mann Whitney U test.
Kurowski et al. Respiratory Research 2014, 15:45 Page 6 of 10
http://respiratory-research.com/content/15/1/45diagnosis of asthma, declared cough and/or dyspnoea with-
out physician-confirmed asthma, presence of atopy or
positive serological test for any respiratory pathogen. Logis-
tic regression analysis using ‘serum CC16 ≤ 4.99 ng/ml’ as a
dependent variable did not show decreased serum CC16
levels to be determined either by predominant endurance
exercise nor by length of the single training session.
Serum IgG immune response to respiratory pathogens
The prevalence of positive serological testing for anti-
PIV, anti-RSV or and anti- M.pneumoniae (but not for
antiadenovirus) antibody, was significantly lower among
athletes than among healthy subjects. The mean serum
concentration of Anti-PIV IgG levels was significantly
lower, whereas concentration of anti-AdV IgG was sig-
nificantly higher in professional athletes - Table 4.
The percentage of positive serological tests and me-
dian serum levels of IgG against respiratory pathogens
did not differ between athletes declaring frequent URTIs
in AQUA questionnaire and the remaining group -
Table 5.
Correlations of serum CC16 and IgG immune response to
respiratory pathogens
In all athletes, a weak yet significant positive correlation
of serum CC16 and IgG concentration was observed
only for PIV (R = 0.20, p < 0.01) but not for the remaining
pathogens. In atopic athletes, positive correlations were ob-
served between the levels of serum CC16 and IgG against
RSV (R = 0.29, p = 0.009), PIV (R = 0.31, p = 0.01) and
Adenovirus (R = 0.27, p = 0.02). No significant correlations
were observed in healthy controls.
Higher anti-adenovirus IgG titres were found in both
atopic and non-atopic athletes as compared to HC (46.4
[23.5-64.8] and 41.6 [25.4-53.3] vs 33.4 [25.8-41.2] EIU,
respectively; median [interquartile range], p < 0.001) -
Figure 3A. Non-atopic athletes had lower anti-PIV IgG
levels than atopic athletes (65.9 [22.6-96.5] vs 88.1 [62.8-
107.6] U/ml; median [interquartile range], p < 0.01),
and lower than HC (65.9 [22.6-96.5] vs 104.8 [68.5-
126.0] U/ml; median [interquartile range], p < 0.001) –
Figure 3B. No significant differences between atopic and
non-atopic athletes and HC were seen with regard toTable 4 Percentage of positive test results and levels of IgG a
olympic-level athletes
Pathogen HC Athletes P
[χPercentage of positive serological tests
PIV 1,2,3 95.7% 74.7% <
RSV 84.4% 68.2% 0
AdV 72.7% 71.3% 0.
M. pneumoniae 100% 90.2% 0
PIV, parainfluenza virus; RSV, respiratory syncytial virus; AdV, adenovirus. Significantanti-RSV and anti-Mycoplasma pneumoniae IgG levels
(data not shown).
When the results of the positive serological testing
were analysed, a significantly lower percentage of sub-
jects with positive anti-RSV serology was observed in
non atopic athletes (60.8%) than in healthy controls
(84.4%, p = 0.001) and atopic athletes (76.3%, p = 0.03).
The presence of a positive RSV serology test was signifi-
cantly associated with atopy (OR = 2.89; 95%CI, 1.34-6.23;
p = 0.007). Such associations were not observed regarding
serological testing for IgG against PIV, adenovirus and
M. pneumoniae – data not shown.
Discussion
This study documents that serum CC16 concentrations
are significantly lower in top athletes than in control
subjects from the general population. Decreased serum
CC16 concentrations were reported in infants and chil-
dren regularly visiting indoor pools [22,23] but other
studies brought conflicting results regarding the effect
of single and repeated training session on serum CC16
[24,25]. Discrepancies are believed to be due to inten-
sity of exertion and breathing pattern employed during
various types of athletic activity (reviewed by LaKind et
al. [11]). Our study, including large and heterogeneous
group has shown decreased serum CC16 levels in pro-
fessional athletes, irrespective of the type or pattern of
high-level activity. However, due to the limited number
of athletes representing each discipline, it was impos-
sible to assess the influence of each type of sport on
serum CC16 concentration. We have not ascertained
any influence of predominant exercise pattern (endur-
ance versus non-endurance) on athletes’ serum CC16
levels. Although withdrawal of swimmers and triath-
letes from the serum CC16 analysis did not influence
final result, these data - in our opinion – are too scarce
to conclude that unfavourable training environment (e.g.,
trichloramine exposure) does not affect serum CC16
concentration.
CC16 is a protein of multifaceted characteristics. It may
be considered both as a marker of the disruption of airway
epithelial barrier integrity and as a co-participant in anti-
inflammatory response. Degree of CC16 involvement andgainst respiratory pathogens in healthy controls (HC) and
value
2 test]
HC Athletes P value
[Mann-Whitney U test]median IgG level
0.0003 99.5 U/ml 32.9 U/ml <0.0001
.01 39.7 EIU 35.3 EIU 0.25
93 33.4 EIU 44.2 EIU 0.0005
.01 66.3 EIU 65.2 EIU 0.38
P values given in bold print.
Table 5 Percentage of positive test results and levels of IgG against respiratory pathogens in athletes with and













Percentage of positive serological tests Median IgG level
PIV 1,2,3 47.2% 52.6% 0.70 25.4 U/ml 33.0 U/ml 0.17
RSV 71.8% 67.5% 0.75 32.8 EIU 35.3 EIU 0.66
AdV 66.7% 72.7% 0.58 43.9 EIU 44.3 EIU 0.66
M. pneumoniae 92.3% 90.9% 0.96 64.3 EIU 65.7 EIU 0.64
PIV, parainfluenza virus; RSV, respiratory syncytial virus; AdV, adenovirus.
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ter of research and dispute.
Our results suggest, that it is an intensive and
regularly performed exercise per se that stimulates air-
way inflammation, irrespective of training intensity.Figure 3 Box and whisker plots presenting serum anti-AdV1,2,3 (pane
healthy controls (HC). Ends of whiskers present minimum and maximumReduced presence of CC16, an anti-inflammatory factor,
may additionally contribute to airway inflammation and
hyperresponsiveness.
In addition, the control non-athletes asthmatic pa-
tients were found to have CC16 levels similar to those inl A) and serum anti-PIV (panel B) IgG levels in athletes and
values in each group; PIV, parainfluenza virus; AdV, adenovirus.
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report, documenting a significant decrease of serum CC16
in asthma [16]. In our opinion, the possible explanation
for this discrepancy is the fact that our asthmatic controls
group comprised exclusively subjects with mild disease
well controlled on anti-inflammatory treatment. There-
fore, it is possible that that changes in serum CC16 level
reflect the grade of airway inflammation in asthma, simi-
larly as it was observed in regard to sputum CC16 in sub-
jects with COPD [26]. Our data suggest that the issue of
CC16 in chronic asthma be extensively studied in a well-
defined population.
Although recent data published by Jacobs et al [27]
show that lower serum CC16 levels may be associated
with allergic sensitisation, no differences in CC16 levels
between atopics and non-atopics were observed in our
population of athletes. Therefore, the associations of
allergic sensitisation with markers of epithelial barrier
disruption require further study.
Another novel observation is that athletes declaring
frequent upper respiratory tract infections had significantly
lower serum CC16 concentrations than those without fre-
quent infections - Figure 2. Accordingly, a higher risk of
frequent respiratory infections was associated with low
serum CC16 level. Low serum CC16 was found to be also
associated with patients’ reported symptoms of rhinitis, but
not with physician-diagnosed rhinitis. This apparent dis-
crepancy may be explained by the fact that symptoms
declared as “rhinitis” were, in fact, symptoms of upper re-
spiratory infections. This is congruous with observation
that both frequent of URTIs and reported rhinitis symp-
toms are considerably more likely to be encountered in
athletes with serum CC16 below 5 ng/ml.
The common belief that moderate exercise is benefi-
cial to one’s health whereas excessive physical training
may considerably increase the susceptibility to infection
was confirmed by the concept of the U-shaped relation-
ship between physical activity and resistance to disease
[5]. Our study comprised top-level athletes and, al-
though only 19.2% of them claimed to be suffering from
frequent respiratory infections, those who reported in-
fections had significantly lower serum CC16 concen-
trations. This interaction is further strengthened by
significant associations of decreased serum CC16 levels
with frequent declared respiratory infections and nasal
symptoms and indicates, that the immune response
against some respiratory pathogens may be modified by
competitive sporting activity. Positive correlation of anti-
PIV IgG and serum CC16 may be considered an indirect
proof for immunomodulatory activity of the latter, but the
lack of such correlation for the remaining pathogens is
somewhat puzzling and suggests the need for further
study of the influence of CC16 on the susceptibility to in-
fection with particular pathogens.Less frequent positive serological test results against
PIV, RSV and M. pneumoniae in professional athletes
compared to controls may be interpreted as indirect evi-
dence for impaired immunocompetence resulting from
continuous high exercise load. In a mouse model, CC16
was shown to influence the lymphocyte response of the
airways after infection with RSV. Mice lacking CC16
demonstrated significantly higher concentrations of Th2
cytokines IL-5 and IL-13 in BALF for several days fol-
lowing the infection [17]. The stimulatory activity of
RSV infection on Th2 cytokine synthesis and release
may explain the association of atopy with more frequent
occurrence of positive testing for anti-RSV IgG in atopic
athletes.
The frequency of positive immune response to RSV
was comparable between atopic athletes and healthy
control subjects, but it was significantly lower in non-
atopic athletes. In addition, correlations between serum
CC16 level and intensity of immune response to respira-
tory viruses (RSV, PIV and adenoviruses) were only sig-
nificant in atopic athletes. Given that serum CC16 levels
in athletes were not seen to be modified by atopy status,
it may suggest, that atopy per se influences the immune
response to respiratory viruses.
Our study has several limitations. The study group
was quite heterogeneous in terms of predominant pat-
tern of exercise and training environment not allowing
for identification of possible effects of any particular
sport on CC16 or immune response against respiratory
pathogens. Accordingly, no standardised and comparable
measures of exercise load/intensity could be included
into analysis. Furthermore, the AQUA question concern-
ing respiratory infections does not determine their actual
frequency, allowing only for the subjective assessment of
whether the URTIs are frequent or not.
Another limitation of our study results from the inter-
subject variability of CC16 levels. Overlaps in the serum
CC16 are observed between the groups and it could be
argued that outliers influence the overall result. Signifi-
cant differences were shown through non-parametric
tests which makes possibility of such influence less likely.
However, this issue should be considered possible con-
founder and addressed in next studies on CC16 in larger
populations.
For the purpose of logistic regression analysis, 5.0 ng/ml
was set arbitrarily as the CC16 threshold value, based on
the reference value given by the manufacturers of the
ELISA kits. However, the CC16 levels in healthy subjects
are variable and the accepted reference values for CC16
are actually lacking, which substantially hinders such ana-
lysis and signals the need for further assessment of CC16
levels in various clinical models [7,24,28].
Bronchial hyperreactivity was assessed only in few pa-
tients (due to their training schedules and low accessibility)
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role of CC16 in the context of bronchial hyperresponsive-
ness may be important for understanding the pathogenesis
of EIB, especially in view of the data showing association of
CC16 gene polymporphism with airway hyperresponsive-
ness and asthma phenotype [29].Conclusions
Our study demonstrated that regular high-load exercise
training is associated with a decrease in serum CC16
protein levels and lower CC16 levels in competitive ath-
letes are associated with increased prevalence of reported
respiratory infections. Further studies are necessary to elu-
cidate the mechanism of association between increased
susceptibility to respiratory infections in top athletes and
epithelial cell injury markers such as CC16.
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